Harvard Apparatus Regenerative Technology
Holliston
About Harvard Apparatus Regenerative Technology
Biostage is a biotechnology company developing esophageal implants for patients battling life-threatening conditions. It uses the patient’s stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed by a surgeon due to cancer, trauma, or birth defects. Once the regeneration is complete, typically after about 3 months, the scaffold is removed via the mouth. It requires no surgical incision to remove the scaffold.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $39.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: otcqb:HRGN
- Website: hregen.com
- Phone: (774)-233-7300
Industries & Categories
Biotechnology, Health Care, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/harvard-apparatus-regenerative-technology-53937 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.